Denosumab in Metabolic Bone Disease in Chronic Intestinal Failure Patients
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Low bone mineral density (BMD) is commonly reported in patients receiving home parenteral
nutrition (HPN). Denosumab represent a new drug, which helped to prevent osteoclast. The aim
of the study was to assess its value in chronic intestinal failure patients.